Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Tuesday, January 30, 2018

Acute or Delayed Systemic Administration of Human Amnion Epithelial Cells Improves Outcomes in Experimental Stroke

When the hell will we get this tested in humans and available as a stroke protocol? NEVER  I BET.
http://stroke.ahajournals.org/content/early/2018/01/29/STROKEAHA.117.019136
Megan A. Evans, Rebecca Lim, Hyun Ah Kim, Hannah X. Chu, Chantelle V. Gardiner-Mann, Kimberly W.E. Taylor, Christopher T. Chan, Vanessa H. Brait, Seyoung Lee, Quynh Nhu Dinh, Antony Vinh, Thanh G. Phan, Velandai K. Srikanth, Henry Ma, Thiruma V. Arumugam, David Y. Fann, Luting Poh, Cameron P.J. Hunt, Colin W. Pouton, John M. Haynes, Stavros Selemidis, William Kwan, Leon Teo, James A. Bourne, Silke Neumann, Sarah Young, Emma K. Gowing, Grant R. Drummond, Andrew N. Clarkson, Euan M. Wallace, Christopher G. Sobey, Brad R.S. Broughton
https://doi.org/10.1161/STROKEAHA.117.019136
Stroke. 2018;STROKEAHA.117.019136
Originally published January 30, 2018

    Abstract

    Background and Purpose—Human amnion epithelial cells (hAECs) are nonimmunogenic, nontumorigenic, anti-inflammatory cells normally discarded with placental tissue. We reasoned that their profile of biological features, wide availability, and the lack of ethical barriers to their use could make these cells useful as a therapy in ischemic stroke.
    Methods—We tested the efficacy of acute (1.5 hours) or delayed (1–3 days) poststroke intravenous injection of hAECs in 4 established animal models of cerebral ischemia. Animals included young (7–14 weeks) and aged mice (20–22 months) of both sexes, as well as adult marmosets of either sex.
    Results—We found that hAECs administered 1.5 hours after stroke in mice migrated to the ischemic brain via a CXC chemokine receptor type 4-dependent mechanism and reduced brain inflammation, infarct development, and functional deficits. Furthermore, if hAECs administration was delayed until 1 or 3 days poststroke, long-term functional recovery was still augmented in young and aged mice of both sexes. We also showed proof-of-principle evidence in marmosets that acute intravenous injection of hAECs prevented infarct development from day 1 to day 10 after stroke.
    Conclusions—Systemic poststroke administration of hAECs elicits marked neuroprotection and facilitates mechanisms of repair and recovery.
    • Received August 22, 2017.
    • Revision received December 14, 2017.
    • Accepted December 15, 2017.
    Posted by at
    Labels: , , , , , , ,

    No comments:

    Post a Comment

    Subscribe to: Post Comments (Atom)